Buprenorphine Conversion Calculator
This page explains how to use the calculator above for formulation reference, MME estimation, and buprenorphine induction-readiness screening. The tool is designed for learning and reference support. It should not be used as a stand-alone prescribing instruction.
About This Calculator
The Buprenorphine Conversion Calculator helps users review buprenorphine formulation information, estimate Morphine Milligram Equivalent (MME) exposure from selected opioids, and screen key readiness factors before buprenorphine initiation. It is intended for pharmacy, medicine, nursing, and clinical education contexts.
What the Calculator Can Do
1. Formulation reference
Compares commonly used buprenorphine formulations and highlights practical dosing notes, route differences, and label-based cautions.
2. MME estimator
Estimates total daily opioid exposure using MME factors for selected opioids. This is an exposure estimate, not a direct opioid rotation dose.
3. Induction readiness
Reviews timing, opioid type, COWS score, fentanyl or methadone exposure, and red flags before considering buprenorphine initiation.
How to Use the Calculator
- Select the correct mode. Use formulation reference for buprenorphine product comparison, MME estimator for opioid exposure, and induction readiness for initiation screening.
- Enter the dose carefully. Confirm whether the input is mg per dose, mg per day, mcg/hour, or another frequency shown in the calculator.
- Review warnings before using the result. The result may show a risk level, caution message, or need for clinical review instead of a simple dose.
- Use references and local policy. Product labels, institutional protocols, and clinician review should override any educational calculator output.
Understanding Each Mode
Formulation Reference Mode
This mode helps explain differences among sublingual films or tablets, buccal films, transdermal patches, and extended-release injections. It should not be treated as a simple mg-to-mg substitution table.
- Sublingual buprenorphine products: Often used as a common reference point for OUD treatment and daily dosing discussions.
- Zubsolv and Bunavail: Different absorption characteristics mean milligram strengths may not match Suboxone or generic sublingual products directly.
- Butrans patch: Should be interpreted using label-based opioid-experience and oral morphine equivalent guidance, not as a direct sublingual buprenorphine conversion.
- Sublocade injection: Should be interpreted using its label-based transition pathway from transmucosal buprenorphine, not as a direct monthly-to-daily conversion.
MME Estimator Mode
This mode estimates total daily MME from selected opioids. MME is useful for exposure comparison and risk awareness, but it should not be used by itself to determine a new opioid dose or buprenorphine dose.
Induction Readiness Mode
This mode focuses on safety screening before buprenorphine initiation. It checks factors such as opioid type, hours since last opioid, COWS score, fentanyl exposure, methadone exposure, pregnancy, sedation concern, and care setting.
Key Safety Concepts
| Topic | Why It Matters | Practical Interpretation |
|---|---|---|
| MME | Compares opioid exposure across different opioid medications. | Use as a risk and exposure estimate only. Do not use as a direct rotation dose. |
| COWS score | Helps assess withdrawal severity before buprenorphine initiation. | Inadequate withdrawal increases the risk of precipitated withdrawal. |
| Fentanyl exposure | Fentanyl may complicate timing because of tissue redistribution and prolonged receptor effects. | May require a more cautious approach, higher observed withdrawal severity, or specialist/local protocol. |
| Methadone exposure | Methadone has a long and variable half-life and higher induction complexity. | Requires extra caution and usually longer waiting periods or specialist oversight. |
| Butrans | Patch dose is expressed as mcg/hour over a 7-day system. | Use label-guided opioid-experience and OME guidance, not direct SL conversion. |
| Sublocade | Monthly extended-release injection has its own transition criteria. | Use label-based transition from transmucosal buprenorphine and monthly dosing instructions. |
When to Be Extra Cautious
- Recent fentanyl use: Risk of precipitated withdrawal may be harder to predict.
- Methadone use: Longer waiting periods and specialist review are often needed.
- Low or absent withdrawal symptoms: Starting too early can trigger precipitated withdrawal.
- Sedation or respiratory concern: Do not proceed without urgent clinical assessment.
- Pregnancy: Use pregnancy-specific clinical guidance and specialist care.
- Concurrent CNS depressants: Benzodiazepines, alcohol, sedatives, and other depressants increase respiratory depression risk.
- Liver disease: Buprenorphine products may require closer assessment and monitoring.
What the Results Mean
- Low, moderate, or high MME risk: This reflects estimated opioid exposure. It does not automatically define the correct buprenorphine dose.
- Proceed with caution: The calculator found one or more risk factors that should be reviewed clinically before initiation or switching.
- Not suitable for direct conversion: This means the formulation should be interpreted using product labeling and clinical context, not a simplified conversion equation.
- Educational estimate only: The result supports learning and structured review, but it should not replace prescribing information or professional judgment.
Common Mistakes to Avoid
- Do not convert Butrans mcg/hour directly into a sublingual buprenorphine dose without label and clinical review.
- Do not convert Sublocade monthly injection into a simple daily sublingual equivalent.
- Do not start buprenorphine when the patient has no or minimal withdrawal unless following a supervised protocol.
- Do not use MME alone to select an induction dose.
- Do not ignore fentanyl, methadone, pregnancy, sedation, or respiratory depression warnings.
- Do not use old MME factors when updated CDC 2022 factors are intended.
Frequently Asked Questions
Is this a direct buprenorphine dose conversion tool?
No. The calculator provides educational estimates, formulation reference information, MME exposure estimates, and induction-readiness screening. Buprenorphine decisions require clinical judgment and patient-specific assessment.
Why does the calculator avoid direct Butrans-to-sublingual conversion?
Butrans is a weekly transdermal system expressed in mcg/hour. Its label uses prior oral morphine equivalent and opioid-experience guidance. A simple sublingual mg/day conversion can be misleading.
Why does the calculator avoid direct Sublocade-to-daily conversion?
Sublocade is an extended-release monthly injection with specific transition and maintenance instructions. It is not best explained as a simple daily sublingual equivalent.
What is MME?
MME means Morphine Milligram Equivalent. It is a standardized estimate used to compare opioid exposure across opioid medications. It is useful for risk review, but not for direct dose switching.
What is COWS?
COWS means Clinical Opiate Withdrawal Scale. It helps assess withdrawal severity before buprenorphine initiation. Starting buprenorphine too early can increase precipitated withdrawal risk.
Why is fentanyl exposure important?
Fentanyl can make initiation timing more difficult. Some guidance recommends confirming adequate withdrawal and using extra caution when fentanyl exposure is likely.
Why is methadone treated with extra caution?
Methadone has a long and variable half-life. Buprenorphine initiation after methadone may require longer waiting periods, careful withdrawal assessment, and specialist or protocol-based care.
Can this calculator be used for chronic pain patients?
It can support education and reference review, but chronic pain and opioid use disorder have different goals, formulations, regulations, and dosing strategies. Product labeling and clinician review remain essential.
References
- Centers for Disease Control and Prevention. CDC Clinical Practice Guideline for Prescribing Opioids for Pain, 2022.
- Substance Abuse and Mental Health Services Administration. Buprenorphine Quick Start Guide.
- Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder.
- DailyMed. BUTRANS buprenorphine transdermal system prescribing information.
- DailyMed. SUBLOCADE buprenorphine extended-release injection prescribing information.
- The American Society of Addiction Medicine. National Practice Guideline for the Treatment of Opioid Use Disorder.
